Pages that link to "Q38152451"
Jump to navigation
Jump to search
The following pages link to Bridging, switching or drug holidays - how to treat a patient who stops natalizumab? (Q38152451):
Displaying 15 items.
- Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations (Q26752859) (← links)
- Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations (Q26765300) (← links)
- Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation (Q33562198) (← links)
- Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis? (Q33562701) (← links)
- Multiple sclerosis reactivation postfingolimod cessation: is it IRIS? (Q34365360) (← links)
- Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo (Q36023188) (← links)
- Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. (Q37696989) (← links)
- Novel monoclonal antibodies for therapy of multiple sclerosis (Q38191996) (← links)
- Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives. (Q38364547) (← links)
- Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologica (Q40067748) (← links)
- Pulsed corticosteroid treatment in MS patients stabilizes disease activity following natalizumab withdrawal prior to switching to fingolimod. (Q41002593) (← links)
- Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads. (Q41386664) (← links)
- Natalizumab discontinuation and disease restart in pregnancy: a case series. (Q51063274) (← links)
- Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod (Q51247242) (← links)
- [Immunotherapies for multiple sclerosis : review and update] (Q86835429) (← links)